- Molodecky NA, Soon S, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54.42.
- Mamoori A, Wahab R, Islam F, Lee K, Vider J, Lu C-T, et al. Clinical and biological significance of miR-193a-3p targeted KRAS in colorectal cancer pathogenesis. Human pathology. 2018;71:145-56.
- Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369(9573):1627-40.
- Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):3-10.
- Roggenbuck D, Reinhold D, Baumgart DC, Schierack P, Conrad K, Laass MW. Autoimmunity in Crohn's disease—a putative stratification factor of the clinical phenotype. Adv Clin Chem. 2016;77:77-101.
- Halmos EP, Gibson PR. Dietary management of IBD—insights and advice. Nat Rev Gastroenterol. Hepatol. 2015;12(3):133-46.
- Connelly TM, Berg AS, Harris III L, Brinton D, Deiling S, Koltun WA. Genetic determinants associated with early age of diagnosis of IBD. Dis Colon Rectum. 2015;58(3):321-7.
- O’Toole A, Korzenik J. Environmental triggers for IBD. Curr Gastroenterol Rep. 2014;16(7):396.
- Zhang Y-Z, Li Y-Y. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20(1):91.
- Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science. 2004;303(5663):1522-6.
- Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17(1):1-14.
- Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS, Levings MK. The role of T‐regulatory cells and Toll‐like receptors in the pathogenesis of human inflammatory bowel disease. Immunology. 2008;125(2):145-53.
- Reid G, Howard J, Gan BS. Can bacterial interference prevent infection? Trends Microbiol. 2001;9(9):424-8.
- Rhee SH, Hwang D. Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NFκB and expression of the inducible cyclooxygenase. J Biol Chem. 2000;275(44):34035-40.
- Rhee SH, Jones BW, Toshchakov V, Vogel SN, Fenton MJ. Toll-like receptors 2 and 4 activate STAT1 serine phosphorylation by distinct mechanisms in macrophages. J Biol Chem. 2003;278(25):22506-12.
- Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21(1):335-76.
- Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000;68(12):7010-7.
- Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Investig. 2004;113(9):1296-306.
- Rhee SH, Im E, Riegler M, Kokkotou E, O'brien M, Pothoulakis C. Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. PNAS. 2005;102(38):13610-5.
- Stanislawowski M, Wierzbicki P, Golab A, Adrych K, Kartanowicz D, Wypych J, et al. Decreased Toll-like receptor-5 (TLR-5) expression in the mucosa of ulcerative colitis patients. J Physiol Pharmacol. 2009;60(Suppl 4):71-5.
|
